Tetrate and Federal Agency NIST Cohost ZTA and DevSecOps Conference 2022 Kicking Off With Istio and Envoy Training
5.1.2022 16:07:00 EET | Business Wire | Press release
Tetrate, the leading company providing a zero-trust application connectivity platform, announced their third annual conference on Zero Trust Architecture (ZTA) and DevSecOps for Cloud Native Applications in partnership with the U.S. National Institute of Standards and Technology (NIST), the federal organization responsible for creating security standards. The NIST–Tetrate multi-cloud conference is a premier event for CISOs, platform architects, and tech leadership from federal and corporate organizations.
The virtual conference will take place on January 27 from 8:00 a.m. – 5:00 p.m. EST and will be preceded by a 2.5-hour training on January 26, showcasing the implementation of Zero Trust Architecture on an actual Platform One deployment. This year’s conference will focus on DevSecOps and ZTA as foundational approaches to developing, deploying, and operating high assurance, cloud native applications. Featured speakers include: André Mendes, Department of Commerce CIO; Kelsey Hightower, Principal Engineer Google Cloud; Ronald Ross, NIST Fellow; and Zack Butcher, Tetrate Founding Engineer. The conference has seen tremendous growth in attendance over the past three years. Past speakers have included Nicolas Chalain, the U.S. Air Force’s first Chief Software Officer, and Zulfikar Ramzan, CTO of RSA Security.
“Cybersecurity incidents are one of the biggest issues facing organizations today, especially as the world moves towards cloud-native applications,” said David Ferraiolo of NIST. “Developing, deploying, and operating zero-trust enabled applications to achieve security, reliability, and resiliency is extremely important for organizations to feel secure.”
“Over the last three years, the NIST–Tetrate conference has featured dialogues and workshops from the world’s most esteemed service mesh and cybersecurity experts," said Varun Talwar, co-founder of Tetrate. "The growth in popularity of the conference is a testament to the importance of ZTA and DevSecOps in a multi-cloud environment. This year, again, we're thrilled to gather together and offer our global community valuable insights and perspectives from top visionaries."
Cloud-native applications often consist of microservices deployed across a combination of public cloud, private cloud, and on-prem, also known as heterogeneous infrastructure. This has created challenges related to connectivity, security, and reliability for delivering high-assurance applications, leading to the popularity of DevSecOps and ZTA. Service mesh plays a critical role in incorporating zero-trust design and DevSecOps principles by adding security and reliability to connect microservices across infrastructures without any additional code.
The conference will feature presentations by domain experts, practitioners, and thought leaders in DevSecOps and Zero Trust Architecture (ZTA) deployments, as well as demonstrations of proof-of-concept use cases in multi-cloud environments. Presentations will address the following:
- ZTA guiding principles and approaches for workflow, system design, and operations through DevSecOps pipelines, authentication and authorization frameworks, and continuous monitoring;
- NIST’s latest guidance on DevSecOps and security engineering practices;
- The role of automation in operational security;
- The benefits of prescribed approaches, such as prevention of configuration drift and continuous authority to operate.
In addition to a lineup of notable speakers, the training on January 26 will help deliver an educational experience where attendees will learn new skills and cover the deployment of a zero-trust platform with the use of Istio, Kubernetes, and other tools to implement the following security components:
- in-app and user-level security permissions,
- encryption in transit,
- enhanced identity and access controls, and
- runtime observability.
Tetrate also provides free passes, on request, to application security professionals who need the $35 fee waived.
Join the virtual event: Registration page
- Join and follow the conversation with hashtag #ZTACon2022 #DevSecOps
- Twitter: @tetrateio
- LinkedIn: Tetrate
- YouTube: Tetrate
For more information regarding ZTA and DevSecOps Conference 2022, an entirely virtual experience taking place this week, please visit: https://www.tetrate.io/zta-devsecops-conference-2022.
About Tetrate–NIST Collaboration
Tetrate and NIST have collaborated over the last three years across multiple deliverables. Using NIST’s experience with cybersecurity and Tetrate’s expertise on secure service mesh, they have collaborated to produce U.S. security standards for a distributed architecture:
- (SP 800-204A) Building Secure Microservices-based Applications Using Service-Mesh Architecture,
- (SP 800-204B) Attribute-based Access Control for Microservices-based Applications using a Service Mesh,
- (SP 800-204C) Implementation of DevSecOps for a Microservices-based Application with Service Mesh, and
- Implementation of Next Generation Access Control (NGAC), a superior authorization framework that’s more fine-grained than role-based access control (RBAC) and attribute-based access control (ABAC), in Tetrate’s products.
About Tetrate
Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Customers get consistent, baked-in observability, runtime security, and traffic management in any environment. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io.
About NIST
The National Institute of Standards and Technology (NIST) was founded by the U.S. Congress in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation's oldest physical science laboratories. From the smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials, and computer chips, innumerable products and services today rely in some way on technology, measurement, and standards provided by NIST.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005433/en/
Contact information
Annie Fink, Bospar
Annie@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 10:00:00 EEST | Press release
ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to operational execution, but organisations cannot scale AI without trust, visibility, and control,” sai
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
